---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-000192"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:34:04.674021+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harrow terminates $18.4M Melt loan, takes ~47% equity stake; appoints Saharek division president

## Summary
- Terminated Loan Agreement with Melt; received 2.26M Series B-1 and 74k Series B preferred shares in full settlement of ~$18.4M outstanding.
- After settlement, Harrow holds ~47% of Melt's equity (including 3.5M common shares) plus royalty rights on Melt drug candidates.
- John P. Saharek appointed President/CEO of ImprimisRx division effective Jan 2, 2024; base salary $450K, target bonus 50%.
- Melt received FDA support for MELT-300 Phase 3 program; expects to begin Phase 3 in Q1 2024, potentially benefiting Harrow's stake.
- Code of Business Conduct and Ethics amended to update corporate name and clarify political activities; no waivers granted.

## SEC filing metadata
- accession: 0001493152-24-000192
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 8.01, 5.02, 5.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-000192
- JSON: https://secwatch.observer/filing/0001493152-24-000192.json
- Plain text: https://secwatch.observer/filing/0001493152-24-000192.txt

## Key facts
- Executive change
  John P. Saharek was appointed as President and Chief Executive Officer of the Company's ImprimisRx division at HARROW, INC..
  - Action: appointed
  - Role: President and Chief Executive Officer of the Company's ImprimisRx division
  source text: Effective January 2, 2024, Harrow, Inc. (the “Company”) appointed John P. Saharek as the President and Chief Executive Officer of the Company’s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm
- Governance Changes
  HARROW, INC.: Amendments to the Code of Business Conduct and Ethics to update corporate name and clarify obligations regarding political activities (effective 2023-12-28).
  - Change: code of ethics
  - Effective: 2023-12-28
  source text: Effective December 28, 2023, the Board of Directors of the Company approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) upon the recommendation of the Nomination and Corporate Governance Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.